TrialDiabetes technology & therapeutics2017

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.

Allen B King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.